Latest research on Olmesartan medoxomil

Olmesartan is an antihypertensive agent, which belongs to the class of medications called angiotensin II receptor blockers. It is indicated for the treatment of high blood pressure and is marketed under the name Olmetec®. The FDA label includes a black-box warning of injury and death to the fetus, so women of child-bearing age need to be warned and take the necessary precautions. Olmesartan is also contraindicated in diabetes mellitus patients taking aliskiren.

Olmesartan medoxomil dosage

In the Olmesartan medoxomil group, the usual recommended starting dose of Olmesartan medoxomil is 20 mg once daily when used as monotherapy in patients who are not volume-contracted. [source, 2016]
For patients requiring further reduction in blood pressure after 2 weeks of therapy, the dose of Olmesartan medoxomil may be increased to 40 mg. [source, 2016]
Briefly, the two Original studies18,19 had a multicenter, randomized, double-blind, parallel group design, consisting of a 2-week washout with placebo, followed by 12 weeks of treatment with Olmesartan medoxomil or Ramipril at initial doses of 10 or 2.5 mg once daily, respectively. [source, 2015]
In a sub-analysis of the TRINITY trial (Triple therapy with Olmesartan medoxomil, Amlodipine, and Hydrochlorothiazide in hypertensive patients; ClinicalTrials.gov number, NCT00649389) the effect of triple combination therapy was assessed, with doses up to 40 mg of olmesartan, 10 mg of Amlodipine, and 25 mg of Hydrochlorothiazide, using ABPM in 440 patients with HTN defined as moderate to severe based on a systolic BP ≥160 mmHg or a diastolic BP ≥100 mmHg. [source, 2015]
We chose the dose of Olmesartan medoxomil and Amlodipine besylate in accordance with a study of Suzuki et al13 and Yoshii et al14 in which the authors demonstrated significant antiatherosclerotic properties of a single treatment with Olmesartan medoxomil or Amlodipine besylate without affecting systolic blood pressure. [source, 2015]
To exclude a possible confounding effect of blood pressure and lipid levels on lesion progression, we chose the dose of Olmesartan medoxomil and Amlodipine besylate based on a study of Suzuki et al13 and Yoshii et al14 where the authors demonstrated significant antiatherosclerotic properties of Olmesartan medoxomil and Amlodipine besylate without affecting systolic blood pressure. [source, 2015]
Although we chose the dose of Olmesartan medoxomil and Amlodipine besylate in accordance with studies that demonstrated antiatherosclerotic properties without affecting blood pressure,13,14 we cannot completely exclude that antiatherosclerotic effects might be related to a reduction in blood pressure. [source, 2015]
There is no relationship between the dose and the occurrence of side effects of Olmesartan medoxomil. [source, 2014]
The dose of 20 mg/d for Olmesartan medoxomil and 500 mg/time for Probenecid were chosen for this study according to the recommended doses in clinic. [source, 2014]
The first dose of Probenecid was administered with Olmesartan medoxomil in the morning of the last day in period II. [source, 2014]